Shanghai Rongrui Pharmaceutical

Shanghai Rongrui Pharmaceutical (operating domestically as the entity of Joint Biosciences) is a clinical-stage biotechnology company specializing in the development of next-generation oncolytic virus therapies and vaccines for solid tumors. Founded by Dr. Guoqing Zhou, the company leverages its proprietary Vesicular Stomatitis Virus (VSV) vector system to engineer tumor cells to express therapeutic targets and antibodies directly within the patient's body. Its core technology platforms include OVV-Mark™ for tumor antigen marking, VSV-Engager™ for localized multi-specific antibody expression, and OVV-Drive-IO™ for combination immunotherapies. The company's lead candidate, OVV-01 (VSV-NY-ESO-1), is currently in Phase II clinical trials in both the US and China for advanced solid tumors, including soft tissue sarcoma, and has received Fast Track and Orphan Drug designations from the US FDA.